Drugs / Autologous CD19 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07681388 | Jan → Dec 2026 expected | pemphigus vulgaris | Jinbo Chen | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD19 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07681388 ↗ |
| Action | Deplete | “peripheral CD19-positive B-cell depletion” NCT07681388 ↗ |
| Modality | Cell therapy | “autologous CD19 CAR-T cell therapy” NCT07681388 ↗ |
| Route | Intravenous | “a single intravenous infusion of autologous CD19 CAR-T cells” NCT07681388 ↗ |
| Target | CD19 | “The CAR construct targets CD19-expressing B cells” NCT07681388 ↗ |